This randomized, placebo-controlled, double-blind trial aims to investigate intranasal OXT as a novel therapeutical option in central diabetes insipidus (cDI) to improve psychological symptoms and socio-emotional functioning. Optionally, patients can present for additional assessments in sub-studies: * fMRI sub-study at day 14 (± 2 days) (one additional visit) * Social-stress sub-study at day 14 (± 2 days) (one additional visit)
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in State-Trait Anxiety Inventory (STAI) questionnaire to assess general anxiety levels
Timeframe: Day 0, day 1, day 14, day 28
Change in EmBody/EmFace to assess recognition of facial and body expressions
Timeframe: Day 0, day 1, day 28
Mirjam Christ-Crain, Prof. Dr. med.